Clinical Trial Results: An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study [Phase 3]

View source ↗

Summary

Open-label long-term safety study results for AXS-05 in dementia of the Alzheimer's type (AD) showing safety observations from ADVANCE-2 and ACCORD-2 extensions…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation in Patients with Dementia of the Alzheimer Type
• Alzheimer Disease

Drugs mentioned

• AXS-05 (dextromethorphan-quinidine)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Status: TERMINATED | Results posted: 2026-06-25